ATE277038T1 - Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung - Google Patents

Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung

Info

Publication number
ATE277038T1
ATE277038T1 AT98962567T AT98962567T ATE277038T1 AT E277038 T1 ATE277038 T1 AT E277038T1 AT 98962567 T AT98962567 T AT 98962567T AT 98962567 T AT98962567 T AT 98962567T AT E277038 T1 ATE277038 T1 AT E277038T1
Authority
AT
Austria
Prior art keywords
chelating agents
oxide releasing
nitrogen oxide
therapeutic use
nitric oxide
Prior art date
Application number
AT98962567T
Other languages
English (en)
Inventor
Robertson Towart
Jan Olof Gustav Karlsson
Lars Goeran Wistrand
H Kan Malmgren
Original Assignee
Amersham Health As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9727226.4A external-priority patent/GB9727226D0/en
Priority claimed from GBGB9805450.5A external-priority patent/GB9805450D0/en
Application filed by Amersham Health As filed Critical Amersham Health As
Application granted granted Critical
Publication of ATE277038T1 publication Critical patent/ATE277038T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
AT98962567T 1997-12-23 1998-12-18 Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung ATE277038T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9727226.4A GB9727226D0 (en) 1997-12-23 1997-12-23 Method
GBGB9805450.5A GB9805450D0 (en) 1998-03-13 1998-03-13 Method
PCT/GB1998/003840 WO1999033823A1 (en) 1997-12-23 1998-12-18 Nitric oxide releasing chelating agents and their therapeutic use

Publications (1)

Publication Number Publication Date
ATE277038T1 true ATE277038T1 (de) 2004-10-15

Family

ID=26312841

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98962567T ATE277038T1 (de) 1997-12-23 1998-12-18 Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung

Country Status (7)

Country Link
US (1) US6391895B1 (de)
EP (1) EP1060174B1 (de)
JP (1) JP2001527072A (de)
AT (1) ATE277038T1 (de)
AU (1) AU1770299A (de)
DE (1) DE69826528T2 (de)
WO (1) WO1999033823A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056328A1 (en) 1999-03-19 2000-09-28 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
AU2001249310A1 (en) * 2000-03-21 2001-10-03 Uab Research Foundation Prevention and/or treatment of diabetes mellitus by pharmacologically inhibitingpancreatic beta-cell o-linked protin glycosylation and/or pancreatic beta-cell p135 o-glycosylation
US20030186948A1 (en) * 2000-03-21 2003-10-02 Jeffrey Kudlow O-linked N-acetylglucosamine pathway in the pathogenesis of neurodegeneration and diabetes
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
ES2232613T3 (es) 2000-04-26 2005-06-01 Cellegy Pharmaceuticals, Inc Formulaciones y metodos de utilizacion de agentes mimeticos del oxido nitrico contra un fenotipo celular maligno.
EP1414432A4 (de) * 2001-08-10 2008-01-09 Nitromed Inc Anwendungsverfahren für neue schwefelhaltige organische nitratverbindungen
US6679827B2 (en) 2001-10-11 2004-01-20 Robert E. Sandstrom Magnetic field enhancement of tumor treatment
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
US6627602B2 (en) 2001-11-13 2003-09-30 Duke University Preventing desensitization of receptors
EP1500402A4 (de) 2002-04-26 2009-12-30 Takeda Pharmaceutical Zelltodhemmer
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US20020168424A1 (en) * 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
KR20050083827A (ko) * 2002-10-24 2005-08-26 이노스 파마슈티칼스, 인코포레이티드 서방성 ｌ-아르기닌 포뮬레이션 및 이의 제조방법 및 용도
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
JP5564158B2 (ja) * 2003-07-09 2014-07-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 亜硝酸塩によって特定の心臓血管状態を処置する方法
US7041286B2 (en) * 2003-07-23 2006-05-09 Nerenberg Arnold P Composition for mitigating a pernicious thrombotic event
CA2540202A1 (en) * 2003-09-29 2005-04-21 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
JP4738352B2 (ja) 2004-02-09 2011-08-03 アミュレット ファーマシューティカルズ インコーポレイティッド 一酸化窒素放出ポリマー
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20070148154A1 (en) * 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
WO2006125123A2 (en) * 2005-05-19 2006-11-23 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
EP1888510A4 (de) 2005-05-27 2013-01-16 Univ North Carolina Stickoxidfreisetzende partikel für stickoxidtherapeutika und biomedizinische anwendungen
KR101678865B1 (ko) * 2007-12-14 2016-11-23 플레드파르마 에이비 암의 치료에 사용하기 위한 화합물들
EP2237788A4 (de) * 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc Aerosolisierte nitrit- und stickoxidspendende verbindungen und ihre verwendung
US20110104308A1 (en) * 2008-05-09 2011-05-05 Duke University Treatment For Diseases Relying On Discovery That Thioredoxin Mediates Nitric Oxide
US8207208B2 (en) * 2008-05-15 2012-06-26 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
CN105688215A (zh) 2009-07-06 2016-06-22 普莱制药公司 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
WO2011050319A2 (en) * 2009-10-23 2011-04-28 Oregon Health & Science University Inhibiting the deleterious effect of anthracyclines
CN105130855B (zh) 2009-12-07 2018-05-25 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物及其用途
DE102010047283B4 (de) 2010-10-01 2012-03-22 Heinz Kiefer Untersuchungsverfahren/Screeningverfahren unter Einbeziehung von lebenden Geweben des Blutgefäß-Systems
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
ES2695173T3 (es) 2011-02-28 2019-01-02 Novan Inc Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas
CN107353313B (zh) 2012-01-05 2019-04-09 普莱制药公司 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法
US20150272988A1 (en) 2012-03-07 2015-10-01 Advanced Inhalation Therapies (Ait) Ltd. Inhalation of nitric oxide for treating respiratory diseases
MX376321B (es) 2012-11-02 2025-03-07 Egetis Therapeutics Ab Usos para el tratamiento de cancer.
KR101555523B1 (ko) * 2014-02-28 2015-09-25 부산대학교 산학협력단 산화질소 방출성 상처치료 필름 및 이의 제조방법
KR20190085967A (ko) * 2016-11-14 2019-07-19 칼슨-튜너 인베스트 에이에스 화학요법으로-유도된 psn을 예방 및 치료하기 위한 비-전이 금속 배위된 디피리독실 화합물의 용도
US20230108186A1 (en) * 2020-02-07 2023-04-06 Know Bio, Llc Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto
KR102462782B1 (ko) * 2021-01-29 2022-11-03 포항공과대학교 산학협력단 환원반응성 일산화질소 공여 화합물 및 전달체 시스템
WO2023038386A1 (ko) * 2021-09-13 2023-03-16 서울대학교산학협력단 일산화질소 생성용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3129906C3 (de) * 1981-07-24 1996-12-19 Schering Ag Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
US4687659A (en) * 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
AR246956A1 (es) * 1987-05-08 1994-10-31 Salutar Inc Compuesto quelante, un intermediario para preparar el mismo, y un procedimiento para preparar una composicion de medio de contraste.
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
JP2833766B2 (ja) * 1987-07-16 1998-12-09 ニユコメド・アクシエセルカペト アミノポリカルボン酸およびその誘導体
HUT59014A (en) * 1988-09-27 1992-04-28 Salutar Inc Process for producing diagnostic compositions comprising chelates
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
WO1993020806A1 (en) * 1992-04-13 1993-10-28 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of nitric oxide/nucleophile complexes for the treatment of cancer
JPH09508097A (ja) * 1993-11-02 1997-08-19 アメリカ合衆国 虚血再灌流傷害における保護剤としての酸化窒素放出化合物の使用
WO1996031217A1 (en) * 1995-04-04 1996-10-10 Duke University Inhibiting retroviral replication
WO1996039409A1 (en) * 1995-06-05 1996-12-12 Nitromed, Inc. Nitrosylated and nitrated superoxide oxidants and reductants
GB9613182D0 (en) * 1996-06-24 1996-08-28 Nycomed Imaging As Method
US20030165985A1 (en) 2001-05-08 2003-09-04 Derry Jonathan M.J. Methods for identifying compounds that antagonize cd40 signaling

Also Published As

Publication number Publication date
JP2001527072A (ja) 2001-12-25
EP1060174B1 (de) 2004-09-22
DE69826528D1 (de) 2004-10-28
EP1060174A1 (de) 2000-12-20
WO1999033823A1 (en) 1999-07-08
DE69826528T2 (de) 2006-02-23
AU1770299A (en) 1999-07-19
US6391895B1 (en) 2002-05-21

Similar Documents

Publication Publication Date Title
DE69826528D1 (de) Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung
DE69716104D1 (de) Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände
BR9811946A (pt) Método para prevenção ou tratamento de distúrbios e doenças dependentes de estrogênio
MY124091A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
DK1039887T3 (da) Anvendelse af aminothiolforbindelser til behandling af neuro- og nefrolidelser og terapeutiske toksiciteter
DE69033299D1 (de) Verwendung von Carnosolsäure wegen seiner anticarcinogenen und antiviralen Eigenschaften
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
IL140159A0 (en) Neuroprotective composition for the prevention and/or treatment of nervous and behavioral alterations due to anxiety states or depression
ITFI980208A0 (it) Derivati anticolinesterasici per il trattamento delle sindromi dolorose funzionali e/o organiche
ATE121727T1 (de) Chelatbildner, die eine ortho-bindende funktionelle gruppe besitzen und komplexe davon.
GB9309387D0 (en) Nitric oxide scavengers
FR2825273B1 (fr) Composition pour le traitement des signes cutanes du vieillissement
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
WO1999011256A8 (en) L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
NO20006699L (no) Forbindelser med veksthormonfrigjörende egenskaper
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
DE60003189D1 (de) Synergistische zusammensetzung, die daunorubicin derivate und antimetabolite enthält
KR960016353U (ko) 형태와 기능이 경혈치료용으로 재구성된 파스
UA42301A (uk) Засіб "камілаль" для лікування і профілактики проктологічних захворювань
IT229231Y1 (it) Dispositivo perfezionato per l'accensione del bruciatore particolarmente nei piani di cottura delle cucine e bruciatore cosi'

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties